- Home
- NVO vs TMUS Comparison
NVO vs TMUS Comparison
Compare NVO & TMUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- TMUS
- Stock Information
- Founded
- NVO 1923
- TMUS 1994
- Country
- NVO Denmark
- TMUS United States
- Employees
- NVO N/A
- TMUS N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- TMUS Telecommunications Equipment
- Sector
- NVO Health Care
- TMUS Telecommunications
- Exchange
- NVO Nasdaq
- TMUS Nasdaq
- Market Cap
- NVO 278.0B
- TMUS 264.8B
- IPO Year
- NVO N/A
- TMUS N/A
- Fundamental
- Price
- NVO $47.20
- TMUS $238.93
- Analyst Decision
- NVO Buy
- TMUS Buy
- Analyst Count
- NVO 6
- TMUS 23
- Target Price
- NVO $112.00
- TMUS $254.80
- AVG Volume (30 Days)
- NVO 20.6M
- TMUS 4.3M
- Earning Date
- NVO 08-19-2025
- TMUS 07-23-2025
- Dividend Yield
- NVO 2.50%
- TMUS 1.47%
- EPS Growth
- NVO 17.93
- TMUS 32.79
- EPS
- NVO 3.40
- TMUS 10.59
- Revenue
- NVO $43,922,211,349.00
- TMUS $84,052,000,000.00
- Revenue This Year
- NVO $13.92
- TMUS $8.67
- Revenue Next Year
- NVO $14.04
- TMUS $5.35
- P/E Ratio
- NVO $13.88
- TMUS $22.56
- Revenue Growth
- NVO 24.11
- TMUS 6.27
- 52 Week Low
- NVO $46.90
- TMUS $185.39
- 52 Week High
- NVO $139.74
- TMUS $276.49
- Technical
- Relative Strength Index (RSI)
- NVO 24.17
- TMUS 53.32
- Support Level
- NVO $46.90
- TMUS $236.91
- Resistance Level
- NVO $49.21
- TMUS $242.79
- Average True Range (ATR)
- NVO 1.57
- TMUS 4.74
- MACD
- NVO -2.13
- TMUS 0.61
- Stochastic Oscillator
- NVO 1.20
- TMUS 50.33
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About TMUS T-Mobile US Inc.
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the US. T-Mobile now serves 80 million postpaid and 25 million prepaid phone customers, equal to around 30% of the US retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves 7 million residential and business customers. In addition, T-Mobile provides wholesale services to resellers.